Deutsche Bank Ag\ Exelixis, Inc. Transaction History
Deutsche Bank Ag\
- $245 Billion
- Q1 2025
A detailed history of Deutsche Bank Ag\ transactions in Exelixis, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 75,820 shares of EXEL stock, worth $3.31 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
75,820
Previous 46,289
63.8%
Holding current value
$3.31 Million
Previous $1.54 Million
81.64%
% of portfolio
0.0%
Previous 0.0%
Shares
37 transactions
Others Institutions Holding EXEL
# of Institutions
613Shares Held
257MCall Options Held
1.57MPut Options Held
730K-
Black Rock Inc. New York, NY33.5MShares$1.46 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA28.7MShares$1.25 Billion0.02% of portfolio
-
Farallon Capital Management LLC San Francisco, CA22.5MShares$984 Million4.78% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny14.8MShares$647 Million0.88% of portfolio
-
State Street Corp Boston, MA11.8MShares$515 Million0.02% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $14.1B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...